Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 938-946

  Stålhammar, Jan ^a   Stern, Lee ^b   Linder, Ragnar ^c   Sherman, Steven ^a   Parikh, Rohan ^a   Ariely, Rinat ^d   Wikström, Gerhard ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b Analytica International   (United States)

^c Pygargus AB   (Sweden)

^d GLAXOSMITHKLINE   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Direct costs; Health care cost; Reduced ejection fraction heart failure; Resource utilization

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; REDUCED EJECTION FRACTION HEART FAILURE; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY; FEMALE; HEALTH RESOURCES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; SWEDEN;

EID: 84865220188     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.686464     Document Type: Article

References (23)

1. Mehta PA, Dubrey SW, McIntyre HF, et al. Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail (2008);10:1108-16
2. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med (1999);246:275-84
3. Somaratne JB, Berry C, McMurray JJ, et al. The prognostic significance of heart failure with preserved left ventricular ejection fraction: A literature-based meta-Analysis. Eur J Heart Fail (2009);11:855-62
4. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004);43:317-27
5. Cline CM, Boman K, Holst M, et al. The management of heart failure in Sweden. Eur J Heart Fail (2002);4:373-6
6. Malmberg I, Persson U. Primary health care costs in connection with heart failure surveyed: Increased use of ACE inhibitors would be beneficial. Lakartidningen (2000);97:2465-70
7. Persson H, Malmqvist K, Carlsson A, et al. More and more persons suffer from heart failure. Better treatment and information are necessary. Lakartidningen (1994);91:3251-4
8. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care (2005);23:227-32
9. Schwinger R. Pathophysiology of heart failure. Clin Res Cardiol Suppl (2010);4:16-20
10. Jonsson A, Edner M, Alehagen U, et al. Heart failure registry: A valuable tool for improving the management of patients with heart failure. Eur J Heart Fail (2010);12:25-31
11. MacKenzie E, Smith A, Angus N, et al. Mixed-method exploratory study of general practitioner and nurse perceptions of a new community based nurseled heart failure service. Rural Remote Health (2010);10:1510
12. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail (2002);4:361-71
13. Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infraction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil (2009);16:576-82
14. Kjeldsen SE, Stalhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens (2010);24:263-73
15. Carlsson A, Borgström F, Stalhammar J, et al. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics (2004); 22(3 Suppl):25-35
16. Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data. Int J Clin Pract (2008);62:708-16
17. Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infarction and stroke on health care costs in the patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil (2009);16:576-82
18. Kjeldsen SE, Stalhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Human Hypertension (2010);24:263-73
19. Henriksson M, Russell D, Bodegard J, et al. Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertens (2010);25:130-6
20. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care (2005);23:227-32
21. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail (2008);10:933-89
22. Heart Failure Performance Measurement Set: American College of Cardiology Foundation (ACCF); American Heart Association (AHA); Physician Consortium for Performance ImprovementR (PCPITM); January 2011. Available at 5http://www.ama-Assn.org/ama1/pub/upload/mm/pcpi/hfset-12-5.pdf4 Last accessed May 2012
23. Andersson B, Kjork E, Brunlof G. Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment. Int J Cardiol (2005);104:257-63